Crestor vs Zetia: Head-to-Head Efficacy Compared

Note on review status: this draft is pending qualified medical review. It has not yet been reviewed or approved by a licensed clinician.

Rosuvastatin (brand name Crestor) is a statin, in the drug class HMG-CoA reductase inhibitor. Ezetimibe (brand name Zetia) is a cholesterol absorption inhibitor that works through a different receptor (NPC1L1) in the intestinal wall. Both are oral, once-daily tablets used to lower LDL cholesterol, and both are FDA-approved and available as generics in the United States. They are not really competitors in most treatment plans; ezetimibe is usually added to a statin rather than used instead of one.

The useful question for most readers is not "which drug is better" but "which problem does each drug solve, and in what order should they be used." That question has a clear answer from guidelines and trial evidence, laid out below.

The short answer: rosuvastatin lowers LDL cholesterol by roughly 45 to 55% as monotherapy, depending on dose, while ezetimibe lowers LDL by roughly 18% on its own. No published randomized trial has directly compared the two drugs head-to-head for cardiovascular outcomes. Rosuvastatin's outcomes evidence comes from the JUPITER trial, which tested rosuvastatin against placebo in adults without known cardiovascular disease. Ezetimibe's outcomes evidence comes from IMPROVE-IT, which tested ezetimibe added to a statin, not ezetimibe alone. Current ACC/AHA guidance treats ezetimibe as a second-line add-on after a statin has been maximized, not as an alternative to a statin in patients who can tolerate one.

How the two drugs lower cholesterol differently

Rosuvastatin blocks HMG-CoA reductase, the enzyme the liver uses to manufacture cholesterol. When hepatic synthesis drops, the liver responds by pulling more LDL particles out of circulation through increased LDL-receptor expression. This is the same mechanism shared by every statin; rosuvastatin and atorvastatin are generally considered the two most potent members of the class at their higher doses.

Ezetimibe acts at the intestinal brush border, inhibiting the NPC1L1 transporter that absorbs dietary and biliary cholesterol. Because it does not touch the liver's own cholesterol production, its effect on LDL is smaller when used alone, but it works through a mechanism that is fully independent of statin action. That independence is the reason the two drugs are so often paired: blocking synthesis and blocking absorption at the same time produces a larger LDL drop than either strategy alone.

What the outcomes trials actually tested

It matters what population and what comparison each trial used, because neither trial tested the question "rosuvastatin versus ezetimibe."

JUPITER (published in the New England Journal of Medicine in 2008) enrolled adults with LDL cholesterol below 130 mg/dL but elevated high-sensitivity C-reactive protein, and randomized them to rosuvastatin 20 mg or placebo. The trial was stopped early after an interim analysis showed a large reduction in the composite cardiovascular endpoint, commonly cited as around a 44% relative risk reduction. This was a primary-prevention population selected for an inflammatory marker rather than for elevated LDL, which is an important boundary on how the result generalizes. Early stopping can also inflate an observed effect size, a limitation raised by independent commentators after publication.

IMPROVE-IT (published in the New England Journal of Medicine in 2015) enrolled patients recently hospitalized for acute coronary syndrome and randomized them to simvastatin plus ezetimibe versus simvastatin plus placebo. The combination arm showed a modest but statistically significant reduction in the composite endpoint over roughly six years of follow-up, commonly cited as around a 6.4% relative risk reduction, with a number needed to treat in the range of 50. This trial tested ezetimibe as an add-on in a high-risk secondary-prevention population, not as a standalone therapy.

Because these two trials tested different drugs against different comparators in different populations, "JUPITER beat IMPROVE-IT" is not a valid conclusion. Both trials support their own guideline position: high-intensity statins as first-line therapy, ezetimibe as an add-on when needed.

The percentage figures above reflect widely cited published results from the JUPITER and IMPROVE-IT trials; reported figures vary between studies and have not been independently confirmed here, so readers should consult the original publications for exact numbers.

Why there is no head-to-head trial

No sponsor has run a large outcomes trial pitting rosuvastatin against ezetimibe as competing monotherapies, and there are structural reasons for that gap rather than an oversight. Guidelines place high-intensity statins first-line for anyone who can tolerate one, which makes it ethically difficult to randomize eligible, statin-tolerant patients to ezetimibe alone for years. A trial large enough to detect a hard-endpoint difference between two LDL-lowering strategies in a low-risk population would also need an unusually large sample size, given how infrequent cardiovascular events are in that group.

Smaller trials have compared LDL-lowering surrogate endpoints between rosuvastatin monotherapy and ezetimibe-statin combinations, generally showing that a statin-ezetimibe combination can match or exceed rosuvastatin's LDL reduction depending on the doses compared. These studies address LDL numbers, not hard cardiovascular outcomes, and readers should not treat surrogate-endpoint comparisons as equivalent to outcomes evidence.

Decision table: which drug fits which situation

This table describes guideline-based sequencing, not an individualized dosing or treatment plan. The right starting point for any specific patient depends on baseline LDL, ASCVD risk calculation, comorbidities, and tolerability, and should be set by the prescribing clinician.

How much LDL reduction to actually expect

Rosuvastatin's dose-response relationship is well established across statin comparison trials: roughly 45 to 55% LDL reduction across the 10 to 40 mg dose range, with the higher end of that range at the top dose. Ezetimibe alone produces roughly an 18% reduction. Added to an existing statin, ezetimibe typically contributes an additional 20-plus percentage points of relative LDL reduction beyond what the statin was already achieving, because the two mechanisms are independent.

As an illustration only, and not a prediction for any individual patient: someone starting near an LDL of 160 mg/dL might reach the 70s on a high-intensity statin alone, the low 130s on ezetimibe alone, and the high 50s to low 60s on the combination. Actual results vary by baseline lipid profile, adherence, diet, and genetics, and should be confirmed with a follow-up lipid panel rather than assumed from population averages.

Effects beyond LDL

Statins have broader lipid effects than ezetimibe. Rosuvastatin also lowers triglycerides (commonly cited in the range of 10 to 35%, dose-dependent) and raises HDL modestly. Ezetimibe's effect on triglycerides and HDL is minimal; its action is largely confined to LDL and total cholesterol. For a patient with mixed dyslipidemia (high LDL plus high triglycerides), a statin addresses more of the lipid panel. For a patient whose only remaining problem is LDL above goal on an already-optimized statin, ezetimibe's narrower mechanism is the point, not a limitation.

Side effects and tolerability

Statins, including rosuvastatin, are associated with muscle symptoms (myalgia) in a meaningful minority of patients in open-label use, though placebo-controlled and nocebo-controlled studies suggest the drug-attributable rate is lower than raw reporting rates suggest. Statins are also associated with a small increase in new-onset diabetes risk, concentrated in people who already have risk factors for diabetes, and with rare but serious risks including myopathy and transaminase elevation. Ezetimibe's tolerability profile is close to placebo in pooled trial data, with mild gastrointestinal symptoms as the most common complaint and no signal for muscle toxicity or significant liver injury.

This difference is exactly why ezetimibe is the guideline-preferred non-statin add-on for patients who need more LDL lowering but cannot tolerate a higher statin dose: it adds LDL reduction through a mechanism that does not overlap with statin-related muscle or metabolic side effects.

Seek urgent medical attention for unexplained, severe muscle pain or weakness with dark urine while on a statin (possible rhabdomyolysis), or for signs of an allergic reaction to either drug. These are uncommon but require prompt evaluation rather than watchful waiting.

Cost and access

Both drugs are available as generics in the United States, and generic pricing is typically far below the branded Crestor or Zetia list price. Exact retail and copay amounts vary by pharmacy, insurer, and formulary tier and change over time, so a specific dollar figure here would go stale quickly; check current pricing with a pharmacy or insurer directly rather than relying on a fixed number. No fixed-dose combination tablet of rosuvastatin and ezetimibe is currently FDA-approved, so patients taking both drugs take two separate tablets; a generic ezetimibe-simvastatin combination tablet does exist for patients who prefer a single pill with a different statin partner.

Where this fits with PCSK9 inhibitors and newer adjuncts

For patients whose LDL remains above goal on a maximized statin plus ezetimibe, the next guideline-recommended step is a PCSK9 inhibitor (evolocumab or alirocumab), an injectable antibody therapy with its own outcomes trial evidence (FOURIER, for evolocumab) showing a substantial additional LDL reduction and a reduction in cardiovascular events on top of statin therapy. PCSK9 inhibitors are more expensive and require injection, which is why guidelines place them after the oral statin-plus-ezetimibe combination rather than as a routine first add-on.

Other oral adjuncts are also under investigation. A randomized phase 2 trial of obicetrapib, a CETP inhibitor, added to stable statin therapy in Japanese subjects reported additional LDL lowering beyond the statin alone (Nicholls et al., 2024). Obicetrapib is investigational and not FDA-approved for clinical use; this is trial evidence in a specific population, not a treatment recommendation, and it should not be confused with an available therapy.

What is established, what is plausible, and what is not established

Established: rosuvastatin produces substantially larger LDL reductions than ezetimibe as monotherapy. Rosuvastatin has a dedicated primary-prevention outcomes trial (JUPITER); ezetimibe's outcomes benefit has been shown only as an add-on to a statin (IMPROVE-IT), in a secondary-prevention population. Current cholesterol guidelines position ezetimibe as a second-line add-on, not a statin substitute, for patients who can tolerate a statin.

Plausible but unproven: that ezetimibe monotherapy meaningfully reduces cardiovascular events in patients who cannot take a statin at all. No dedicated outcomes trial has tested this scenario, so the assumption rests on LDL-lowering logic (the "lower is better" hypothesis) rather than direct trial evidence in that specific population.

Not established: any direct, trial-based ranking of rosuvastatin versus ezetimibe as competing first-line monotherapies for cardiovascular event reduction. That comparison has not been run and, for ethical and practical reasons described above, is unlikely to be run.

Common questions

Is Crestor better than Zetia? For LDL-lowering power alone, yes: rosuvastatin lowers LDL substantially more than ezetimibe as monotherapy, and it has its own primary-prevention outcomes trial. But the two drugs are typically used together rather than as alternatives, so "better" depends on whether the question is about starting therapy or optimizing an existing regimen.

Can you take rosuvastatin and ezetimibe together? Yes. Combining the two is a guideline-supported strategy when a statin alone does not bring LDL to goal, because the drugs act through independent mechanisms. This should be started and monitored by the prescribing clinician, with a follow-up lipid panel.

Does ezetimibe reduce heart attack risk on its own? No dedicated outcomes trial has tested ezetimibe as monotherapy for cardiovascular event reduction. The only outcomes evidence available (IMPROVE-IT) tested it added to a statin.

If I cannot tolerate a statin, is ezetimibe a reasonable substitute? It is a reasonable option to discuss with a clinician after confirming true statin intolerance, since some LDL lowering is generally preferable to none. Its cardiovascular benefit as a standalone therapy has not been directly proven in an outcomes trial, which is worth knowing before assuming it offers the same protection as a statin.

What comes after a statin plus ezetimibe if LDL is still too high? Guidelines point to a PCSK9 inhibitor as the next step for very high-risk patients who remain above goal on maximized oral therapy.

References

• Nicholls SJ, et al. Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 Trial (2024). https://pubmed.ncbi.nlm.nih.gov/38569868/
• U.S. Food and Drug Administration, Drugs@FDA database, for current approval status and labeling of rosuvastatin and ezetimibe: https://www.accessdata.fda.gov/scripts/cder/daf/
• ClinicalTrials.gov search for ongoing and completed trials of rosuvastatin, ezetimibe, and combination lipid-lowering therapy: https://clinicaltrials.gov/

The JUPITER, IMPROVE-IT, STELLAR, and FOURIER trial results discussed above are drawn from their well-known published summaries. Specific numeric claims attributed to these trials should be verified against their original publications in the New England Journal of Medicine and American Journal of Cardiology before this article is published, since this draft's source citations could not be independently confirmed.